Lucia Baratto

Significant improvements in treatments for children with cancer have resulted in a growing population of childhood cancer survivors who may face long-term adverse outcomes. Here, we aimed to diagnose high-dose methotrexate–induced brain injury on [18F]FDG PET/MRI and correlate the results with cognitive impairment identified by neurocognitive testing in pediatric cancer survivors.

MATERIALS AND METHODS The Institutional Review Board approved this study, and all subjects gave written informed consent. We prospectively enrolled pediatric cancer survivors who were diagnosed with lymphoma, leukemia, or sarcoma and were treated with HDMTX. The inclusion criteria were as follows: cancer patient undergoing HDMTX therapy (≥1,000 mg/m2), age between 6 and 30 y, and written informed consent.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.